Hypofractionated whole breast radiotherapy with or without hypofractionated boost in early stage breast cancer patients: a mono-institutional analysis of skin and subcutaneous toxicity-Reference-Cited by-同舟云学术

Hypofractionated whole breast radiotherapy with or without hypofractionated boost in early stage breast cancer patients: a mono-institutional analysis of skin and subcutaneous toxicity

Published:2018-10-19 Issue:3 Volume:26 Page:290-304
ISSN:1340-6868
Container-title:Breast Cancer
language:en
Short-container-title:Breast Cancer

Author:

Palumbo Isabella,Mariucci Cristina,Falcinelli Lorenzo,Perrucci Elisabetta,Lancellotta Valentina,Podlesko Anna Maria,Marcantonini Marta,Saldi Simonetta,Bini Vittorio,Aristei Cynthia

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12282-018-0923-z.pdf

Reference30 articles.

1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011; 378:1707–16.

2. Vrieling C, van Werkhoven E, Maingon P, Poortmans P, Weltens C, Fourquet A, European Organisation for Research and Treatment of Cancer, Radiation Oncology and Breast Cancer Groups, et al. Prognostic factors for local control in breast cancer after long-term follow-up in the EORTC boost vs no boost trial: a randomized clinical trial. JAMA Oncol. 2017;3:42–8.

3. Owen JR, Ashton A, Bliss JM, Homewood J, Harper C, Hanson J, et al. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncol. 2006;7:467–71.

4. Yarnold J, Ashton A, Bliss J, Homewood J, Harper C, Hanson J, et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiother Oncol. 2005;75:9–17.

5. Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, START Trialists’ Group, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14:1086–94.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acute and Long-Term Toxicity after Planned Intraoperative Boost and Whole Breast Irradiation in High-Risk Patients with Breast Cancer—Results from the Targeted Intraoperative Radiotherapy Boost Quality Registry (TARGIT BQR);Cancers;2024-05-30

2. CANTO‐RT : Skin toxicities evaluation of a multicentre large prospective cohort of irradiated patients for early‐stage breast cancer;International Journal of Cancer;2022-06-30

3. Factors Associated with Late Local Radiation Toxicity after Post-Operative Breast Irradiation;The Breast Journal;2022-04-16

4. Evidence-based guidelines for hypofractionated radiation in breast cancer: conclusions of the Catalan expert working group;Clinical and Translational Oncology;2022-02-21

5. Risk Factors Related to Acute Radiation Dermatitis in Breast Cancer Patients After Radiotherapy: A Systematic Review and Meta-Analysis;Frontiers in Oncology;2021-11-29